USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Aug 15, 2022 | Jun 2022 | - | - | $-0.17 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Aug 15, 2022 | Jun 2022 | - | - | $208.47K |
Invo Bioscience's next earnings date is Monday, Aug 15, 2022 for the fiscal quarter ending Jun 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 2 | $-0.32 | $-0.55 | $-0.09 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 0 / 0 | $-0.32 | $-0.03 | $-0.03 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 2 | $9.70M | $8.75M | $10.65M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Mar 28, 2022 | Dec 2021 | $-0.22 | - | - |
Nov 15, 2021 | Sep 2021 | $-0.20 | $-0.24 | -20.00% |
Aug 16, 2021 | Jun 2021 | $-0.19 | $-0.17 | 10.53% |
May 17, 2021 | Mar 2021 | $-0.18 | $-0.25 | -42.86% |
Mar 30, 2021 | Dec 2020 | $-0.24 | $-0.60 | -150.00% |
Nov 16, 2020 | Sep 2020 | - | $-0.57 | - |
Sep 30, 2020 | Jun 2020 | - | $-0.36 | - |
Jun 30, 2020 | Mar 2020 | - | $-0.27 | - |
Mar 31, 2020 | Dec 2019 | - | $-0.32 | - |
Dec 31, 2019 | Sep 2019 | - | $-0.16 | - |
Sep 30, 2019 | Jun 2019 | - | $-0.15 | - |
May 15, 2019 | Mar 2019 | - | $-0.05 | - |
Dec 31, 2018 | Dec 2018 | - | $-0.16 | - |
Sep 30, 2018 | Sep 2018 | - | $-0.06 | - |
Jun 30, 2018 | Jun 2018 | - | $-0.41 | - |
Mar 31, 2018 | Mar 2018 | - | $-0.03 | - |
Dec 31, 2017 | Dec 2017 | - | $-0.05 | - |
Sep 30, 2017 | Sep 2017 | - | $-0.03 | - |
Jun 30, 2017 | Jun 2017 | - | $-0.03 | - |
Mar 31, 2017 | Mar 2017 | - | $-0.05 | - |
Dec 31, 2016 | Dec 2016 | - | $-0.06 | - |
Sep 30, 2016 | Sep 2016 | - | $-0.05 | - |
Jun 30, 2016 | Jun 2016 | - | $-0.34 | - |
Mar 31, 2016 | Mar 2016 | - | $-0.04 | - |
Dec 31, 2015 | Dec 2015 | - | $-0.06 | - |
Sep 30, 2011 | Sep 2011 | - | $-0.04 | - |
Jun 30, 2011 | Jun 2011 | - | $-0.13 | - |
Apr 15, 2011 | Mar 2011 | $-0.32 | $-0.64 | -100.00% |
Dec 31, 2010 | Dec 2010 | $-0.32 | $-0.64 | -100.00% |
Nov 22, 2010 | Sep 2010 | $-0.32 | $-0.00 | 98.84% |
Aug 20, 2010 | Jun 2010 | $-0.32 | $-0.32 | - |
Apr 6, 2010 | Mar 2010 | - | $0.29 | - |
Dec 31, 2009 | Dec 2009 | - | $-0.32 | - |
Sep 30, 2009 | Sep 2009 | - | $-2.02 | - |
Jun 30, 2009 | Jun 2009 | - | $-0.26 | - |
Mar 31, 2009 | Mar 2009 | - | $-0.39 | - |
Dec 31, 2008 | Dec 2008 | - | $-1.05 | - |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Mar 28, 2022 | Dec 2021 | $-0.78 | $-0.66 | - |
Mar 30, 2021 | Dec 2020 | $-0.98 | $-1.81 | - |
Mar 31, 2020 | Dec 2019 | - | $-0.68 | - |
Dec 31, 2018 | Dec 2018 | - | $-0.66 | - |
Dec 31, 2017 | Dec 2017 | - | $-0.16 | - |
Dec 31, 2016 | Dec 2016 | - | $-0.49 | - |
Dec 31, 2015 | Dec 2015 | - | $-0.86 | - |
Dec 31, 2010 | Dec 2010 | - | $-0.67 | - |
Dec 31, 2009 | Dec 2009 | - | $-2.99 | - |
Dec 31, 2008 | Dec 2008 | - | $-1.05 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Mar 28, 2022 | Dec 2021 | $880.00K | - | - |
Nov 15, 2021 | Sep 2021 | $330.00K | $218.87K | 0.66% |
Aug 16, 2021 | Jun 2021 | $410.00K | $208.47K | 0.51% |
May 17, 2021 | Mar 2021 | $590.00K | $196.57K | 0.33% |
Mar 30, 2021 | Dec 2020 | $440.00K | $196.57K | 0.45% |
Nov 16, 2020 | Sep 2020 | - | $336.07M | - |
Sep 30, 2020 | Jun 2020 | - | $246.07K | - |
Jun 30, 2020 | Mar 2020 | - | $258.57K | - |
Mar 31, 2020 | Dec 2019 | - | $328.57K | - |
Dec 31, 2019 | Sep 2019 | - | $303.57K | - |
Sep 30, 2019 | Jun 2019 | - | $658.64K | - |
May 15, 2019 | Mar 2019 | - | $189.43K | - |
Dec 31, 2018 | Dec 2018 | - | $154.99K | - |
Sep 30, 2018 | Sep 2018 | - | $125.03K | - |
Jun 30, 2018 | Jun 2018 | - | - | - |
Mar 31, 2018 | Mar 2018 | - | - | - |
Dec 31, 2017 | Dec 2017 | - | $81.36K | - |
Sep 30, 2017 | Sep 2017 | - | $68.22K | - |
Jun 30, 2017 | Jun 2017 | - | - | - |
Mar 31, 2017 | Mar 2017 | - | - | - |
Dec 31, 2016 | Dec 2016 | - | $9.52K | - |
Sep 30, 2016 | Sep 2016 | - | $17.83K | - |
Jun 30, 2016 | Jun 2016 | - | - | - |
Mar 31, 2016 | Mar 2016 | - | - | - |
Dec 31, 2015 | Dec 2015 | - | - | - |
Sep 30, 2011 | Sep 2011 | $50.00K | $12.88K | 0.26% |
Jun 30, 2011 | Jun 2011 | $40.00K | - | - |
Apr 15, 2011 | Mar 2011 | - | - | - |
Dec 31, 2010 | Dec 2010 | - | $29.66K | - |
Nov 22, 2010 | Sep 2010 | - | - | - |
Aug 20, 2010 | Jun 2010 | - | - | - |
Apr 6, 2010 | Mar 2010 | - | - | - |
Dec 31, 2009 | Dec 2009 | - | $6.91K | - |
Sep 30, 2009 | Sep 2009 | - | $2.85K | - |
Jun 30, 2009 | Jun 2009 | - | - | - |
Mar 31, 2009 | Mar 2009 | - | - | - |
Dec 31, 2008 | Dec 2008 | - | - | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Mar 28, 2022 | Dec 2021 | $2.10M | - | - |
Mar 30, 2021 | Dec 2020 | $1.28M | $1.04M | -18.96% |
Mar 31, 2020 | Dec 2019 | - | $1.48M | - |
Dec 31, 2018 | Dec 2018 | - | $494.38K | - |
Dec 31, 2017 | Dec 2017 | - | $282.14K | - |
Dec 31, 2016 | Dec 2016 | - | $50.90K | - |
Dec 31, 2015 | Dec 2015 | - | $11.69K | - |
Dec 31, 2010 | Dec 2010 | - | $67.65K | - |
Dec 31, 2009 | Dec 2009 | - | $63.20K | - |
Dec 31, 2008 | Dec 2008 | - | $37.99K | - |
INVO's next earnings date is Monday, Aug 15, 2022 for the fiscal quarter ending Jun 30, 2022.
Invo Bioscience's previous earnings date was May 16, 2022 for its fiscal quarter ended Mar 31, 2022.
Invo Bioscience's previous annual earnings date was Mar 30, 2021 for its fiscal year ended Dec 31, 2020.
INVO's earnings per share (EPS) was $-1.81, missing the consensus analysts forecast of $-0.98 by 84.20% , and lower than the previous year's EPS (Dec 2019) by 167.44%.
Revenues were $1.04M, worse than the forecast of $1.28M by -18.96%, and down by -29.92% from previous year's revenue.
The company reported a net income of $-8.35M.
Invo Bioscience reported a free cash flow of $-4.86M for its fiscal year, compared to $1.26M a year ago.
The company ended the fiscal year with $775.02K in total debt, an increase of 106.14% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.